R. WAYNE RUNDLES, M.D., F.A.C.P.; EARL N. METZ, M.D.; H. R. SILBERMAN, M.D.
Allopurinol, 4-hydroxypyrazolo (3,4-d) pyrimidine (4-HPP),* recently introduced as a new type of agent useful in the treatment of gout, developed from studies undertaken to increase the therapeutic efficacy of 6-mercaptopurine (6-MP) and related thiopurines in leukemia. Since the biologically active form of 6-MP is its ribonucleotide (Figure 1) (1-4), all reactions leading to the removal of 6-MP from this anabolic pathway would decrease its activity. Studies on the metabolic fate of 6-MP in the mouse (5) and the human (6-9) have shown that the major catabolic pathway is oxidative. About 25 to 30% of the total dose of 6-MP is
RUNDLES RW, METZ EN, SILBERMAN HR. Allopurinol in the Treatment of Gout. Ann Intern Med. 1966;64:229–258. doi: https://doi.org/10.7326/0003-4819-64-2-229
Download citation file:
Published: Ann Intern Med. 1966;64(2):229-258.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use